Kwalite Pharmaceuticals Limited has announced that its Board of Directors will convene on February 12, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key corporate governance milestone as the pharmaceutical company prepares to disclose its financial results for the third quarter of fiscal year 2026.

Board Meeting Details

The board meeting has been scheduled in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided comprehensive details regarding the upcoming corporate event.

Financial Results Scope

The board will deliberate on both standalone and consolidated financial results for the quarter ended December 31, 2025. This comprehensive review will provide stakeholders with insights into the company's operational and financial performance during the third quarter of the current fiscal year.

Trading Window Restrictions

Kwalite Pharmaceuticals has implemented trading window closure measures in compliance with regulatory requirements. The company had previously issued an intimation on December 26, 2025, regarding the commencement of the trading window closure.

Regulatory Compliance

The announcement demonstrates the company's adherence to SEBI regulations governing listed entities. The formal notification was submitted to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, ensuring proper disclosure to the stock exchange and market participants.

The communication was signed by Ramesh Kumar, Managing Director (DIN: 00462656), emphasizing the company's commitment to transparent corporate governance practices and timely regulatory compliance.

Kwality Pharmaceuticals Ltd has announced the appointment of Mr. Bhavesh Mahajan as Additional Independent Director, effective January 28, 2026. The Board of Directors approved the appointment on the recommendation of the Nomination and Remuneration Committee during their meeting held on January 28, 2026.

Appointment Details

The appointment encompasses specific terms and regulatory compliance requirements as outlined by the company.

Professional Background

Mr. Bhavesh Mahajan brings extensive professional expertise to the Board. He is a Chartered Accountant with over 19 years of experience in audit and assurance, banking audits, direct and indirect taxation, financial consultancy, and corporate advisory services. He serves as Senior Partner of M/s Bhavesh Mahajan & Co., Chartered Accountants, Amritsar, a Category-II CA firm empaneled with the Reserve Bank of India since 2005.

His professional experience includes:

• Statutory audits and internal audits
• Bank and concurrent audits
• GST advisory services
• Forensic accounting
• Financial and strategic planning
• Regulatory compliance management

Qualifications and Certifications

Mr. Mahajan holds membership with the Institute of Chartered Accountants of India (ICAI) and possesses multiple professional certifications including DISA, Forensic Accounting & Fraud Detection, Concurrent Audit of Banks, GST Certification, and Artificial Intelligence for Chartered Accountants.

He has served as empaneled faculty for ICAI covering Ethics, Taxation, and Professional Development programmes. Additionally, he has held leadership positions including Vice Chairman and Secretary of the Amritsar Branch of ICAI.

Regulatory Compliance

Kwality Pharmaceuticals confirmed that Mr. Bhavesh Mahajan satisfies the independence criteria prescribed under the Companies Act, 2013 and SEBI Listing Regulations. The company stated that he is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. The appointment disclosure complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Mahajan is not related to any existing Director of the company, ensuring independence in his directorial role. The appointment strengthens the company's governance structure with his extensive financial and regulatory expertise.